4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Analyst Ratings
USA - NASDAQ:FDMT - US35104E1001 - Common Stock
10.8 USD
+0.63 (+6.19%)
10.9 USD
+0.1 (+0.93%)
ChartMill assigns a Buy % Consensus number of 81% to FDMT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 31.04. This target is 187.38% above the current price.
FDMT was analyzed by 16 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about FDMT.
In the previous month the buy percentage consensus was at a similar level.
FDMT was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-11 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-12 | Roth Capital | Maintains | Buy -> Buy |
| 2025-08-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-01-13 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | B of A Securities | Maintains | Buy -> Buy |
| 2024-11-21 | Morgan Stanley | Initiate | Underweight |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-23 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-09-19 | Leerink Partners | Reiterate | Outperform -> Outperform |
| 2024-09-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight |
4D MOLECULAR THERAPEUTICS IN / FDMT FAQ
Can you provide the average price target for 4D MOLECULAR THERAPEUTICS IN stock?
16 analysts have analysed FDMT and the average price target is 31.04 USD. This implies a price increase of 187.38% is expected in the next year compared to the current price of 10.8.
How do analysts rate 4D MOLECULAR THERAPEUTICS IN (FDMT)?
The consensus rating for 4D MOLECULAR THERAPEUTICS IN (FDMT) is 81.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.